Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host an event focused on IPH4502, its proprietary Nectin-4 ADC. The event will be held in person and virtually on Wednesday, November 18, 2026 at 11:00 AM ET / 4:00 PM GMT, in London, at the IET London, Savoy Place.

Professor Yohann Loriot, M.D., Ph.D. (Gustave Roussy) will join company management to discuss Phase 1 clinical data from the IPH4502 dose-escalation study being presented at the 2026 EORTC-NCI-AACR (ENA) Symposium.

The event will include a review of the Phase 1 study's safety, pharmacokinetic and antitumor activity findings, along with a discussion of the current treatment landscape and unmet medical need in urothelial cancer. Professor Loriot will provide his clinical perspective, while Innate management will discuss the scientific rationale for IPH4502 and next steps in its clinical development.

A live question-and-answer session will follow the formal presentations.

• Event: IPH4502 Phase 1 clinical data and development outlook

• Date and time: November 18, 2026 at 11:00 a.m. ET / 4:00 p.m. GMT

• Location: IET London, Savoy Place, 2 Savoy Place, London WC2R 0BL, United Kingdom

• To register for in person participation or virtual access, click here.

A replay will be available in the investors section of Innate Pharma website after the event.

Professor Yohann Loriot is a medical oncologist and Professor of Medicine at Gustave Roussy, specializing in genitourinary cancers, with a particular focus on bladder cancer. He serves as Deputy Head of the Department of Therapeutic Innovation and Early Drug Development (DITEP) and coordinates the UNLOCK program, dedicated to understanding mechanisms of sensitivity and resistance to innovative cancer therapies.

He holds both a Medical Degree and a PhD in Anticancer Pharmacology and teaches at Paris-Saclay University. His research focuses on the development of novel therapeutic strategies and the identification of mechanisms of treatment resistance in solid tumors, particularly urothelial and prostate cancers.

Professor Loriot has authored more than 300 peer-reviewed scientific publications and is an active member of several leading international scientific societies, including ESMO, ASCO and AACR. He also leads the EORTC Urological Tumours Group and contributes to the development of European clinical guidelines in bladder cancer.

Scientific expert disclosure Professor Yohann Loriot will participate as guest speaker and Gustave Roussy will receive compensation for his participation in the event, which doesn’t constitute an endorsement of the investigational product or a recommendation for its use.

IPH4502 is Innate Pharma's proprietary Nectin-4 antibody-drug conjugate (ADC), built on three differentiated components. The payload is exatecan, a potent topoisomerase I inhibitor, with the potential to overcome key limitations associated with monomethyl auristatin E (MMAE)-based ADCs, including multidrug resistance protein 1 (MDR1)-mediated resistance, and without the need for CYP2D6 genotyping. IPH4502 incorporates a proprietary stable linker designed to slow the release of free exatecan into the circulation. The binder is a proprietary humanized anti-Nectin-4 antibody with high affinity and a distinct, non-overlapping epitope compared with enfortumab vedotin (EV). In preclinical studies, IPH4502 demonstrated anti-tumor activity in EV-resistant tumor models and in tumors with low and heterogeneous Nectin-4 expression, supporting its potential applicability across solid tumor types beyond urothelial carcinoma (UC). IPH4502 is currently being evaluated in the Phase 1 IPH4502-101 study (NCT06781983) in patients with advanced solid tumors known to express Nectin-4. IPH4502 is currently under clinical development and has not received marketing authorization in the European Union or approval from the U.S. Food and Drug Administration (FDA). Its safety and efficacy have not been established for any commercial use. The product is not available for commercial distribution.